Jump to content

Saurabh Saha

From Wikipedia, the free encyclopedia
Saurabh Saha
NationalityAmerican
EducationBSc, MSc, MD, and PhD
Alma materCalifornia Institute of Technology
Johns Hopkins University
Harvard University
University of Oxford
OccupationCancer drug discovery
Known forTranslational medicine
Cancer biosurgery

Saurabh Saha is an American biotech entrepreneur.[1]

Education

[edit]

Saha received his undergraduate degree in biology from the California Institute of Technology.[2] He also attended both Harvard Business School and Oxford University.[3] Saha trained under Bert Vogelstein during his studies at the Johns Hopkins School of Medicine,[4] where he received both an MD and a PhD in cancer genetics.[5]

Career

[edit]

After finishing graduate school, Saha joined the management consulting firm McKinsey & Company in their Pharmaceuticals and Medical Products Practice in New York City.[6] In 2005, he became the Director of the New Indications Discovery Unit at the Novartis Institutes for BioMedical Research based in Cambridge, Massachusetts.[5] Between 2008 and 2015, Saha served as the President of BioMed Valley Discoveries[7] [3] Saha serves as a venture partner for the life sciences venture capital firm, Atlas Venture and also served as the Chief Medical Officer for its portfolio company, Synlogic.[8]

In 2016, Saha was appointed as President and CEO of Delinia, a biotech company focused on developing novel therapies for the treatment of cancer and autoimmune diseases such as lupus, inflammatory bowel disease, rheumatoid arthritis and others.[9] [10] [11]

Saha has published in periodicals where he and his colleagues reported translational research and development discoveries in cancer research.[12][13][14][15][16][17][18] He is also on the editorial boards of the American Journal of Clinical Oncology,[19] Journal of Translational Medicine,[20] and Cancer Biology & Therapy.[21]

References

[edit]
  1. ^ "Executive Profile". Bloomberg.
  2. ^ "Commencement" (PDF). Retrieved September 19, 2014.
  3. ^ a b "Saurabh Saha". Retrieved September 15, 2014.
  4. ^ Alice Park (August 13, 2014). "Treating Cancer With Bacteria Shows Real Promise". Time Magazine. Retrieved September 15, 2015.
  5. ^ a b "Saurabh Saha". Retrieved September 15, 2014.
  6. ^ "Biomed Valley Discoveries". Retrieved September 19, 2014.
  7. ^ Mitch Leslie (August 13, 2014). "Bacteria shrink tumors in humans, dogs". Science Magazine. Retrieved September 15, 2014.
  8. ^ Fidler, Ben (September 14, 2016). "Sofinnova, Atlas Put $35M Into Delinia to Tackle Autoimmune Diseases". Xconomy.
  9. ^ Carroll, John (September 14, 2016). "Atlas Partner Saha Takes the Helm at Delinia, Looking to Disrupt Autoimmune R&D". Endpoints News.
  10. ^ Adams, Ben (January 26, 2017). "Celgene Splashes Out $300M on Delinia Autoimmune Biotech Buy". FierceBiotech.
  11. ^ Gormley, Brian (January 26, 2017). "Celgene to Pay Up to $775 Million to Buy Biotech Startup Delinia". The Wall Street Journal.
  12. ^ Saha S; Sparks AB; Rago C; Akmaev V; Wang CJ; Vogelstein B; Kinzler KW; Velculescu VE (May 2002). "Using the transcriptome to annotate the genome". Nature Biotechnology. 20 (5): 508–12. doi:10.1038/nbt0502-508. PMID 11981567. S2CID 12709815.
  13. ^ Christoph Lengauer; Luis A. Diaz, Jr & Saurabh Saha (May 2005). "Outlook: Cancer drug discovery through collaboration". Nature Reviews Drug Discovery. 4 (5): 375–380. doi:10.1038/nrd1722. PMID 15864266. S2CID 1720653.
  14. ^ Saurabh Saha; et al. (October 11, 2001). "A Phosphatase Associated with Metastasis of Colorectal Cancer". Science. 294 (5545): 1343–1346. doi:10.1126/science.1065817. PMID 11598267. S2CID 42104960. Retrieved September 15, 2014.
  15. ^ Bardelli, Alberto; Parsons, D. Williams; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Saha, Saurabh; Markowitz, Sanford; Willson, James K. V.; Parmigiani, Giovanni; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E. (May 2003). "Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers". Science. 300 (5621): 949. doi:10.1126/science.1082596. PMID 12738854. S2CID 85934154.
  16. ^ Roberts, Nicholas J.; et al. (Aug 2014). "Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses". Science Translational Medicine. 6 (249). doi:10.1126/scitranslmed.3008982. PMC 4399712. PMID 25122639.
  17. ^ Bardelli, Alberto; Parsons, D. Williams; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Saha, Saurabh; Markowitz, Sanford; Willson, James K. V.; Parmigiani, Giovanni; Kinzler, Kenneth W.; Vogelstein, Bert; Velculescu, Victor E. (9 May 2003). "Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers". Science. 300 (5621): 949. doi:10.1126/science.1082596. PMID 12738854. S2CID 85934154.
  18. ^ Roberts, Nicholas J.; Zhang, Linping; Janku, Filip; Collins, Amanda; Bai, Ren-Yuan; Staedtke, Verena; Rusk, Anthony W.; Tung, David; Miller, Maria; Roix, Jeffrey; Khanna, Kristen V.; Murthy, Ravi; Benjamin, Robert S.; Helgason, Thorunn; Szvalb, Ariel D.; Bird, Justin E.; Roy-Chowdhuri, Sinchita; Zhang, Halle H.; Qiao, Yuan; Karim, Baktiar; McDaniel, Jennifer; Elpiner, Amanda; Sahora, Alexandra; Lachowicz, Joshua; Phillips, Brenda; Turner, Avenelle; Klein, Mary K.; Post, Gerald; Diaz, Luis A.; Riggins, Gregory J.; Papadopoulos, Nickolas; Kinzler, Kenneth W.; Vogelstein, Bert; Bettegowda, Chetan; Huso, David L.; Varterasian, Mary; Saha, Saurabh; Zhou, Shibin (13 August 2014). "Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses". Science Translational Medicine. 6 (249): 249ra111. doi:10.1126/scitranslmed.3008982. PMC 4399712. PMID 25122639.
  19. ^ "Editorial board". Retrieved September 15, 2014.
  20. ^ "Editorial board". Retrieved September 15, 2014.
  21. ^ "Editorial board". Retrieved September 15, 2014.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Saurabh_Saha&oldid=1217699446"